Westpark Capital Issues Positive Forecast for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price

Enanta Pharmaceuticals (NASDAQ:ENTA) had its target price lifted by Westpark Capital from $24.00 to $28.00 in a research note issued to investors on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Other analysts have also recently issued reports about the stock. JMP Securities upped their target price on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 12th. Wall Street Zen raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, June 22nd. HC Wainwright started coverage on shares of Enanta Pharmaceuticals in a research report on Monday, July 28th. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Evercore ISI reduced their price objective on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a research report on Monday, September 15th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $21.00.

Enanta Pharmaceuticals Trading Down 21.0%

Shares of NASDAQ ENTA opened at $11.97 on Tuesday. The firm’s 50-day moving average price is $8.19 and its 200-day moving average price is $6.91. The stock has a market capitalization of $255.92 million, a price-to-earnings ratio of -2.77 and a beta of 0.84. Enanta Pharmaceuticals has a 12-month low of $4.09 and a 12-month high of $15.34.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.25) by $0.40. The firm had revenue of $18.31 million for the quarter, compared to analysts’ expectations of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. On average, equities analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Farther Finance Advisors LLC increased its position in shares of Enanta Pharmaceuticals by 11,558.0% during the second quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 5,779 shares during the period. US Bancorp DE purchased a new position in shares of Enanta Pharmaceuticals during the first quarter worth approximately $36,000. GAMMA Investing LLC purchased a new position in shares of Enanta Pharmaceuticals during the first quarter worth approximately $40,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Enanta Pharmaceuticals during the second quarter worth approximately $88,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth approximately $66,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.